Therapeutic bronchoscopy for malignant central airway obstructions caused by non‐bronchogenic cancers: Results from the EpiGETIF registry
Clément Daigmorte,Daniela Usturoi,Clément Fournier,Frederic Wallyn,Christine Lorut,Valentin Héluain,Julien Mazières,Julien Legodec,Bruno Escarguel,Thomas Egenod,Laurent Cellerin,Nicolas Favrolt,Samy Lachkar,Adrian Crutu,Amandine Briault,Christophe Gut‐Gobert,Valerian Bourinet,Juliette Camuset,Perrot Loïc,Pascal Schlossmacher,Michele Porzio,Antoine Luchez,Jean‐Michel Vergnon,Marie‐Christelle Pajiep Chapda,Pascalin Roy,Hervé Dutau,Nicolas Guibert
DOI: https://doi.org/10.1111/resp.14723
IF: 6.9
2024-04-19
Respirology
Abstract:Background and Objective Little is known about malignant central airway obstruction (MCAO) complicating the metastatic spread of non‐bronchogenic solid cancers (NBC) and their bronchoscopic management. This study aimed to describe the epidemiology of this population and determine prognostic factors before therapeutic bronchoscopy (TB). Methods In this multicenter study using the EpiGETIF registry, we analysed patients treated with TB for MCAO caused by NBC between January 2019 and December 2022. Results From a database of 2389 patients, 436 patients (18%) with MCAO and NBC were identified. After excluding patients with direct local invasion, 214 patients (8.9%) were analysed. The main primaries involved were kidney (17.8%), colon (16.4%), sarcoma (15.4%), thyroid (8.9%) and head and neck (7.9%) cancers. Most patients (63.8%) had already received one or more lines of systemic treatment. Obstructions were purely intrinsic in 58.2%, extrinsic in 11.1% and mixed in 30.8%. Mechanical debulking was used in 73.4% of cases, combined with thermal techniques in 25.6% of cases. Airway stenting was required in 38.4% of patients. Median survival after TB was 11.2 months, influenced by histology (p = 0.002), performance status (p = 0.019), initial hypoxia (HR 1.45 [1.01–2.18]), prior oncologic treatment received (HR 1.82 [1.28–2.56], p
respiratory system